Axiom Catalyst

Severe care disparities, barriers to diagnosis, harrowing patient stories, historically low survival… and yet… enduring hope for women worldwide.While significant progress has been made to address needs of women with gynecologic cancers, and the last 12 month have seen huge strides in advancing standards of care, key challenges remain including the inclusivity of clinical studies, asymmetric engagement and awareness across communities, and limited ability to tailor therapies, especially in later lines as care options dry up.In this this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Dan Simpson, Carlie Darefsky, Harish Venkatesan and Flannery Nania talk through the challenges and hope for patients, as we look to the healthcare industry to raise the bar on health standards.This short podcast complements the specific infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian and endometrial cancers respectively. Let's keep raising awareness and saving lives! 

Dr. Han Phan is a member of the Pediatric Advisory Board at the FDA, and the Director of Rare Disease Research center. She joins the Axiom Table with Akash Bhattacharjee. This discussion goes though her experience with diagnosing and treating Duchenne patients, challenges faced by manufacturers in this space, and one of the most eagerly anticipated news of the year in Pharma. 

May is ALS Awareness Month and this year Axiom is marking it with a dedicated podcast to help raise awareness about amyotrophic lateral sclerosis (ALS) also known as motor neuron disease. ALS is fatal with the average life expectancy after diagnosis being two to five years, although some patients may live for years or decades. There is still no known cure for ALS and current treatment options primarily target symptoms to improve quality of life, rather than stopping the disease progression. In this episode of Axiom Catalyst, Anna Graca is speaking with Dr Tim Williams from the Newcastle MND Care and Research Centre about how this devastating disease affects each individual differently and tremendous efforts of treating physicians and care coordinators to provide a personalised support to these patients and their families. 

There are~ 30 million people in Europe alone living with a rare condition, of which 75% have neurological symptoms. While significant progress has been made to address needs of these patients, key challenges remain including the scarcity of the expertise and fragmentation of research efforts that translate into delayed diagnosis, few disease modifying therapies, and difficulty in accessing adequate care. In this episode of Axiom Catalyst, we invited Frédéric Destrebecq, the Executive Director of the European Brain Foundation and European Brain Council to discuss how coordinated efforts between patient organisations, research and clinical networks, drug innovators and policy makers, can tackle these challenges and reduce the high burden posed by rare neurological disorders in Europe and beyond.

While significant therapeutic advances are underway for inherited blood disorders such as sickle cell disease, hemophilia and β-thalassemia, key challenges remain for the commercialization of these therapies, as well as disparities in access to these treatments and level of care received by patients. In this episode of Axiom Catalyst, we invited John James, CEO of Sickle Cell Society to discuss the impact of sickle celldisease on day-to-day lives of patients living in the UK, as well as current challenges in their clinical journey. We also explore the outreach work done by the Sickle Cell Society including key local initiatives such as the Hackney engagement project, and the translatory impact of their patient support work.

Join Nicole, Kiana, and Madelyn's discussion on updates seen at ASCO GU 2023. We analyze some of the most anticipated read outs in RCC, bladder, and prostate cancers and consider what this data means for physicians and patients.

Join Justin, Rodrigo and Eriko's discussion on bispecific antibody and CAR-T therapies. These innovative options are increasingly becoming available in late-line treatments for heme cancers. In this episode, we cover the advantages and disadvantages of bispecific and CAR-T treatments, emerging CRS considerations, as well as future directions for both modalities in how they pertain to myeloma and lymphoma treatment.

Join Mahim, Samy, & Aman on exciting updates following the ASCO Gastrointestinal Cancers Symposium data readouts as we start 2023 with some exciting updates. In this episode, we share the latest news following recent approvals, 3-year data readouts, and developments in Gastrointestinal, Pancreatic, Colorectal, Hepatocellular Carcinoma, and Biliary Tract Cancer.

Join Mahim and Allegra's discussions on the latest developments in gynecologic oncology as we wrap up 2022 and enter into the new year. In this episode, we recap the impact of antibody drug-conjugate approvals in cervical and ovarian cancers, new PARP inhibitor data in ovarian cancer, and exciting immunotherapy results in frontline endometrial cancer.

In collaboration with Nick Gherardin from University of Melbourne, and Hafiz, Anne has recently co-authored a review article in Frontiers in Oncology about the novel clinical strategies companies are taking to bring gamma delta-inspired therapies to the clinic. Anne Cherry joins the Axiom Catalyst with Mahim Misra to discuss her paper and some of the exciting developments in gamma delta inspired therapies.

Dr. John Tsai, former President of Global Drug Development and CMO of Novartis, joins the Axiom Table with Hafiz Sikder. The conversation spans the changing landscape of Immuno-Oncology, AI, and the impact of COVID-19.

Michelle Werner, CEO Partner of Flagship Pioneering and CEO of Alltrna, joins Hafiz Sikder to discuss her work and role at Alltrna as well as her personal investment in the field. She dives deep into the impact of tRNA on drug development, premature stop codons, and her drive to do more for rare disease.

Join us as we discuss the latest developments in RCC coming out of ESMO22. In this episode, we recap the impact of 3 failed checkpoint-based regimen trials within the (neo)adjuvant setting and the first positive triplet data for advanced RCC.

Join us as Rohan and Andrew discuss key takeaways from an impactful ESMO22 in NSCLC. In this episode, we recap the first Phase III data for a KRASG12C inhibitor, long-term follow-up from checkpoint-based regimens, and the first ADC approval in lung.

Dr. Hope Rugo, University of California at San Francisco, joins Hafiz Sikder for an engaging discussion on the world of Breast Cancer. The discussion ranges from key ESMO data, the future of care, and healthcare disparities.

Join in this week as we review key data-set from ESMO as well as a deep dive into RCC, lung and pan-tumor discussions. Join in the discussion with your POV, comments, and questions.

Axiom Catalyst is live from Gustave Roussy! Hafiz Sikder joins Dr. Barlesi and the leading cancer treatment team in Villejuif, France for a discussion on the future of oncology.

Live from the congress floor! Join Mahim Misra and Maressa Cumbermack for part 2 of our ASCO Snacks series, a quick download on the day's most exciting events. Axiom Catalyst will record live at the 2022 American Society of Clinical Oncology's Annual Meeting in Chicago.

Live from the congress floor! Join Mahim Misra, Charlotte Caine, and Maressa Cumbermack for part 1 of our ASCO Snacks series, a quick download on the day's most exciting events. Axiom Catalyst will record live at the 2022 American Society of Clinical Oncology's Annual Meeting in Chicago.

Vicky Kuo, MS, and Rohan Gidvani, PhD, join Hafiz and Mahim this week to discuss cell and gene therapy before ASCO 2022. Tune in for insights on challenges and emerging technologies from the Axiom Table.

Dr. Hossein Borghaei, Fox Chase Cancer Center, joins Hafiz and Mahim today to discuss updates in TIGIT, Immunotherapy, and more.

On Wednesday April 27, ASCO released 2800+ abstract titles spanning all major tumor types. On today's podcast, we will give you a glimpse into some of the impactful abstracts that will be presented at ASCO in June. Topics will range from practice changing Phase III results from ADCs to emerging modalities like CAR-engineered allogeneic γδ T cells.

Subscribe to the Axiom Catalyst! We will meet weekly to give you timely, holistic updates in life sciences.